Related Experiment Video
Updated: Aug 18, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer
Kiyoshi Mori1, Yukari Kamiyama, Tetsuro Kondo
1Department of Thoracic Diseases, Tochigi Cancer Center, Yonan, Utsunomiya, Japan. kmori@tcc.pref.tochigi.jp
Background:
To evaluate the efficacy and safety of combination chemotherapy of cisplatin (5-day continuous infusion) and docetaxel for the treatment of previously untreated patients with advanced non-small-cell lung cancer (NSCLC).
Materials And Methods:
Eligible patients had an ECOG performance status of 0-2 with measurable NSCLC. Patients received continuous infusion cisplatin 20 mg/m2/day on 5 days and bolus docetaxel 60 mg/m2/day (day 1; PiD therapy) at a 4-week interval.
Results:
Forty-three patients were enrolled. The mean number of cycles administered per patient was 2, and ranged from 1 to 4. The response rate was 49% (95% confidence interval, 33.9-63.8%). The median survival time was 47 weeks and the 1-year survival rate was 47%. The major toxic effects were grade 3 or 4, neutropenia (88%), leukopenia (81%), thrombocytopenia (14%) and anemia (42%). There were no treatment-related deaths.
Conclusion:
PiD therapy was a well-tolerated and active regimen for patients with advanced NSCLC. The major toxicity was neutropenia.
Related Concept Videos
01:11Clinical Trials: Overview
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...